Latest News

Simbec-Orion Modernizing Quality and Compliance with Veeva Vault Quality Suite

18/05/2022

Implementing Veeva Vault Quality Suite applications will help Simbec-Orion increase efficiency through digital execution, as well as strengthen QA processes, driving quality and oversight across our operations. Read the press release here. You might also be interested in reading our news about Alison Hughes, Head of Business Enablement at Simbec-Orion, being recognised as a Veeva […]

Read More

Meet the Team | Tracy Thomas

13/05/2022

We are excited to launch a new blog series where we talk to members of our more than 400- strong team about why they enjoy their role at Simbec-Orion. We previously spoke with Dr Maria Kozlak on a day in the life of a CRA. This month we are speaking with Tracy Thomas, Head of […]

Read More

Lupuzor™ Phase III Trials: Partnering With Immupharma

03/02/2022

Lupuzor™ is an in-development treatment for Lupus, a chronic inflammatory disease thought to affect around 5 million people worldwide. Having recently undergone FDA approval, Lupuzor™ is commencing into phase 3 clinical trials. Simbec-Orion are proud to have been selected by ImmuPharma as a partner to conduct the international phase 3 trial of Lupuzor™ involving pharmacokinetic […]

Read More

Using biomarker clinical trial design to drive rare respiratory disease results

03/02/2022

Simbec-Orion recently helped a biotech sponsor demonstrate the safety and tolerability of a new trial treatment for idiopathic pulmonary fibrosis (IPF). Devising an effective umbrella trial design adapted to the needs of IPF patients, we were able to deliver final CSR results ahead of time. Our researchers devised and conducted the umbrella study design testing […]

Read More

Pulmonary Deposition of BUD/Glycopyrrolate/Formoterol in COPD Patients

18/10/2021

A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered dose inhaler in patients with moderate‑to‑very severe chronic obstructive pulmonary disease. Simbec-Orion worked with two leading organisations, Astra Zeneca and Cardiff Scintigraphics, to successfully complete a scintigraphy study in COPD patients. About the COPD study Study Title A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered […]

Read More

Fundraising for Findacure for Rare Disease Day 2021 

01/03/2021

As a CRO specialising in clinical trials for rare and orphan diseases, Rare Disease Day has become a special cause to us. This year we wanted to give something back to the rare disease patient community and offer our employees the chance to get their families involved in some creative fundraising activities. Inspired by 2021’s […]

Read More

Read our latest article – Rare disease clinical trials continue, thanks to new technology

01/03/2021

Rare Disease Day offers a valuable opportunity to raise awareness of rare disease and campaign for health equity. We are delighted to take part in Health Awareness’ Rare Diseases campaign this year, which in addition to our own contribution, features articles from Genetic Alliance UK, Rare Diseases International and EURORDIS to offer a diverse range […]

Read More

Got a question?
Get in Touch or Submit an RFI/RFP

Our team is on hand to answer any questions you might have relating to the work we do at Simbec-Orion. Just fill in the form below, making sure to tick the boxes that apply, and we’ll respond as quickly as we can.

Looking to volunteer for a clinical trial?

Visit our dedicated volunteer website here, or email [email protected]

Follow us on Social Media

Name(Required)
Opt In Emails